HighTower Advisors LLC lifted its stake in Balchem Co. (NASDAQ:BCPC – Free Report) by 15.3% in the third quarter, HoldingsChannel reports. The firm owned 2,229 shares of the basic materials company’s stock after purchasing an additional 295 shares during the period. HighTower Advisors LLC’s holdings in Balchem were worth $391,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the stock. nVerses Capital LLC purchased a new stake in Balchem during the third quarter valued at about $35,000. GAMMA Investing LLC raised its holdings in shares of Balchem by 73.4% during the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 356 shares during the period. Blue Trust Inc. lifted its position in shares of Balchem by 642.5% in the 3rd quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 726 shares in the last quarter. TD Asset Management Inc acquired a new position in Balchem in the 2nd quarter worth approximately $200,000. Finally, Heritage Family Offices LLP purchased a new position in Balchem during the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.
Balchem Stock Down 0.6 %
BCPC stock opened at $165.49 on Monday. The company has a 50 day moving average of $174.99 and a two-hundred day moving average of $169.82. The company has a market cap of $5.38 billion, a price-to-earnings ratio of 44.49, a PEG ratio of 5.32 and a beta of 0.67. Balchem Co. has a 12-month low of $135.84 and a 12-month high of $186.03. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21.
Balchem Increases Dividend
Analysts Set New Price Targets
BCPC has been the subject of a number of research analyst reports. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th. HC Wainwright increased their price objective on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.
View Our Latest Research Report on Balchem
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Further Reading
- Five stocks we like better than Balchem
- What is a Dividend King?
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- Breakout Stocks: What They Are and How to Identify Them
- CarMax Gets in Gear: Is Now the Time to Buy?
- Insider Trades May Not Tell You What You Think
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.